Onco-Innovations Limited
ONCO.NE
CBOE CA0.65
CAD
- -
- -
Onco-Innovations Limited
ONCO.NE
(CBOE CA)
Recent
price
0.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Onco-Innovations Limited is a Canadian oncology company engaged in cancer research and treatment, with headquarters in Calgary, Alberta, and operations focused on the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, advanced nanoparticle-based tumor delivery, and an AI-native discovery platform. Founded in 2024 and publicly listed on the Canadian market, the company develops its lead program ONC010, a nanoparticle-encapsulated PNKP inhibitor intended to support next-generation DNA damage response therapies for cancers resistant to traditional treatments. The company’s core products and services center on preclinical drug discovery and development, including proprietary oncology drug candidates; PNKP inhibitor technology; nanoparticle formulation and drug-delivery systems; analytical and chemistry, manufacturing and controls support; biomarker and translational research capabilities; and AI-enabled oncology research through its wholly owned Inka Health subsidiary. Onco-Innovations targets the oncology market and seeks to advance therapies for difficult-to-treat solid tumors, with a business model oriented toward research, development, and potential partnering or licensing rather than commercial product sales. In 2025 and 2026, the company materially expanded its platform through several strategic actions, including the acquisition of Inka Health Corp. to accelerate AI-driven cancer research and drug development, an expression of interest with Quantify Research for healthcare data analytics collaboration, and the establishment of Onco-Innovations AU Pty. Ltd. in Australia to support planned Phase I activities. The company also announced a term sheet for a notional CAD$5 million performance-based funding arrangement, a non-brokered LIFE offering, and continued financing amendments, while advancing ONC010 manufacturing and development milestones such as a 300g API scale-up, polymer process development, metabolism studies, and a July 2026 analytical reference standard program completed with Dalton Pharma Services.